Fertility

Egg quality and sperm quality are mitochondrial questions. A mature human oocyte carries on the order of 100,000 mitochondrial DNA copies — vastly more than any other cell in the body — because fertilization, the first cleavage divisions, blastocyst formation, and implantation are all energy-expensive events that draw on the egg's mitochondrial endowment. Sperm motility, capacitation, and the acrosome reaction are direct mitochondrial output; the midpiece of a single sperm is a tightly wound spiral of mitochondria. When oxidative stress in the gonads outpaces the antioxidant systems that keep redox in balance, mitochondrial DNA accumulates damage, ATP production falls, and gamete quality follows. Five products on this page are the most-studied, trial-validated oral interventions for that exact problem.

The 60-second answer

If you only read one section: the fertility stack on this page is built on five compounds with the strongest human-trial evidence for redox protection of eggs and sperm — CoQ10 400mg, N-Acetyl Cysteine 600mg, Reduced Glutathione 500mg, Astaxanthin 12mg, and PQQ 20mg. The published pretreatment window in IVF and pre-conception trials is 60–90 days — that's one full oocyte maturation cycle and roughly one full spermatogenic cycle (74 days). Plan supplementation to start at least 60 days before any cycle, attempted conception, or retrieval. Every product is dosed at the level used in the published human trials cited below, third-party tested for identity and contaminants, and manufactured in cGMP-compliant facilities. This is supplementation to support normal reproductive cellular health — it is not a fertility treatment, not a substitute for medical evaluation, and not a substitute for a fertility specialist's protocol.

On this page

Why egg and sperm quality are mitochondrial questions

Reproduction is the most metabolically demanding biological event most cells will ever attempt. The single mature oocyte that ovulates each cycle has spent decades arrested in prophase I of meiosis, accumulating mitochondrial DNA copies and damage from every metabolic insult its host experienced over the same span. The 100,000-copy mitochondrial endowment isn't excess — it's a battery sized for the explosive ATP demand of meiotic resumption, fertilization, and the first cleavage divisions, all of which happen before the embryo turns on its own genome. If that battery is degraded, every downstream step fails or proceeds at lower fidelity.

Sperm have the opposite problem. Each cell is small, packs almost no cytoplasm, has no transcriptional capacity, and depends on a tight spiral of 70–80 mitochondria in the midpiece to generate every ATP that drives flagellar motion. Sperm membranes are also unusually rich in polyunsaturated fatty acids — the most peroxidation-vulnerable lipid class. The combination is why human sperm samples are uniquely sensitive to oxidative stress: lipid peroxides degrade the membrane, motility collapses, and the acrosome reaction needed to penetrate the zona pellucida fails.

The reproductive science consensus on the central role of oxidative stress is unambiguous: reactive oxygen species in excess of the antioxidant capacity of the gonads is a major driver of age-related decline in egg and sperm quality (Agarwal 2008, Reproductive Biology and Endocrinology; Bentov 2010, Fertility and Sterility; Aitken 2014, Antioxidants & Redox Signaling; Dutta 2019, Andrologia). The Cochrane reviews on antioxidants in subfertility — Smits 2019 for males, Showell 2020 for females — found low-to-moderate quality evidence that oral antioxidant supplementation may improve clinical pregnancy and live-birth outcomes in subfertile couples. That is exactly the framing you would expect if the underlying problem is redox-driven mitochondrial wear, and exactly the framing this collection is designed against.

Five mechanisms of oxidative reproductive aging

1. Mitochondrial DNA damage in the oocyte

Mitochondrial DNA lacks the protective histone packaging of nuclear DNA and sits adjacent to the electron transport chain, where reactive oxygen species are produced as a byproduct of ATP generation. Decades of arrested meiosis mean the human oocyte's mitochondrial DNA has been exposed to that environment longer than any nuclear DNA in the body. Bentov 2010 reviewed the evidence that mitochondrial DNA mutation load rises with maternal age and correlates with reduced fertilization rate, abnormal embryo cleavage, and lower implantation. Mitochondrial bioenergetic support and antioxidant defense are the two levers that meaningfully slow this process in published trials.

2. Endogenous CoQ10 decline in ovarian tissue

Ben-Meir 2015 (Aging Cell) showed that oocytes from older mice had reduced expression of mitochondrial CoQ10 biosynthetic enzymes (Coq6, Coq7, Coq9) and lower mitochondrial CoQ10 content, with a parallel reduction in oocyte mitochondrial activity. CoQ10 supplementation in the same animal model restored ovarian reserve markers, improved oocyte mitochondrial activity, and raised litter size. The same group then ran the human trial that motivates the entire CoQ10 fertility literature — see the next section.

3. Sperm membrane lipid peroxidation

The spermatozoon's plasma membrane is roughly 40% polyunsaturated fatty acids, dominated by docosahexaenoic acid (DHA, 22:6). Polyunsaturated fatty acids carry the highest peroxidation index of any biological lipid class — every additional double bond multiplies vulnerability. Peroxidation chains propagate across the membrane, fluidity collapses, motility falls, and the acrosomal cap that mediates oocyte penetration is compromised. Astaxanthin's documented ability to span the bilayer and quench both hydrophilic and hydrophobic radical species is the mechanistic argument for the Comhaire 2005 trial result.

4. Glutathione depletion in follicular fluid and sperm

Reduced glutathione (GSH) is the cell's primary water-soluble antioxidant and the substrate that glutathione peroxidase uses to neutralize hydrogen peroxide. Paszkowski 1995 (Human Reproduction) and Yeh 2005 reported that reduced GSH concentrations in follicular fluid correlate with oocyte quality, fertilization rate, and embryo grade. On the male side, sperm GSH content correlates with motility and DNA-fragmentation index. Glutathione depletion is the redox bottleneck both gametes share, and it is the bottleneck that the NAC-glutathione substrate-and-product pair is designed to relieve.

5. Bioenergetic shortfall — not enough mitochondria, not enough ATP

Beyond protecting existing mitochondria, fertility outcomes also track with the absolute mitochondrial mass and ATP-generating capacity of the gamete. Mitochondrial biogenesis — the cellular process that constructs new mitochondria — is regulated by PGC-1α (peroxisome-proliferator-activated receptor gamma coactivator 1-alpha) and its downstream effectors NRF1, NRF2, and TFAM. PQQ has been characterized as a small-molecule activator of this pathway in cell models (Chowanadisai 2010, Journal of Biological Chemistry) and in healthy adult humans by mitochondrial-mass markers (Harris 2013). Where CoQ10 and astaxanthin protect existing mitochondria, PQQ helps build new ones — the long-term complement to immediate antioxidant defense.

The trial evidence behind every compound

CoQ10 — the egg-quality flagship

Bentov 2014 (Fertility and Sterility) randomized women aged 38–46 undergoing IVF to 600mg CoQ10/day versus placebo for at least 8 weeks of pretreatment. The trial was halted early after early positive signal made continued randomization to placebo ethically untenable; reported trends were favorable for oocyte aneuploidy and chromosomal segregation. Xu 2018 (Reproductive Biology and Endocrinology) randomized 169 poor-responder Chinese women (POSEIDON Group 4) to 600mg CoQ10/day for 60 days before ovarian stimulation versus no pretreatment, and reported significantly higher retrieved oocyte counts, fertilization rate, and high-quality embryo rate in the CoQ10 arm. Florou 2020 (Journal of Assisted Reproduction and Genetics) reviewed 12 CoQ10 fertility studies and concluded the strongest signal was in IVF pretreatment of older women and poor responders. Male-side: Safarinejad 2009 (Journal of Urology) randomized 212 men with idiopathic oligoasthenoteratozoospermia to 300mg CoQ10/day for 26 weeks versus placebo, with significant improvement in sperm density, motility, and morphology, and increased semen plasma CoQ10 and α-tocopherol concentrations. Sandor 2005 reported analogous improvements in motility at 200mg/day. The dose curve across these trials is steady from 200mg to 600mg/day with the strongest egg-quality signals at 600mg; 400mg/day is the maximum-strength single-softgel dose this collection carries.

N-Acetyl Cysteine — the glutathione substrate

NAC is the most-evidenced cysteine donor for glutathione synthesis and has the strongest fertility data among precursors. Salehpour 2017 (Reproductive BioMedicine Online) compared 1.2g NAC/day to metformin in clomiphene-resistant PCOS patients and found comparable ovulation and pregnancy rates — meaningful because metformin is the standard pharmacological alternative. Devi 2018 reported NAC plus clomiphene improved ovulation rate, endometrial thickness, and pregnancy rate versus clomiphene alone in PCOS-related anovulatory infertility. Thakker 2015 meta-analysis of NAC in PCOS pooled eight randomized trials and concluded NAC improved ovulation rate, pregnancy rate, and live birth rate. Male side: Ciftci 2009 (Urology) randomized 60 men with idiopathic infertility to 600mg NAC/day for 3 months versus placebo, with significant improvement in volume, motility, and viscosity. Safarinejad 2011 added NAC to selenium and reported synergistic improvement in sperm forward motility. NAC is also the bridge to GlyNAC — Sekhar 2021 in healthy older adults showed glycine + NAC normalized red-cell glutathione, oxidative-stress markers, mitochondrial function, and biological-age markers.

Reduced Glutathione — the master antioxidant directly

Glutathione is what every cell, including the oocyte and the spermatozoon, actually uses to neutralize hydrogen peroxide and lipid peroxides via glutathione peroxidase. Reduced GSH levels in follicular fluid correlate with oocyte quality and fertilization rate (Paszkowski 1995, Human Reproduction; Yeh 2005). Direct oral GSH supplementation has been historically dismissed on bioavailability grounds but Richie 2015 (European Journal of Nutrition) demonstrated dose-dependent rises in red-cell GSH and lymphocyte GSH after 6 months of 250mg or 1000mg/day oral GSH, and a separate Sechi 1996 trial documented improvements in sperm motility and forward progression with parenteral GSH. The collection's GSH product is enteric-coated for small-intestinal release, where uptake of intact GSH and its constituent amino acids is highest. Pair with NAC for substrate-and-product coverage: NAC supplies the rate-limiting cysteine, GSH provides the immediate-availability molecule.

Astaxanthin — the membrane antioxidant for sperm motility and oocyte membranes

The Comhaire 2005 trial (Asian Journal of Andrology) randomized 30 men with oligoasthenoteratozoospermia to 16mg astaxanthin/day or placebo for 3 months alongside their partners' assisted reproduction protocol. Sperm linear velocity, capacitation index, and zona-binding score all improved significantly versus placebo, and the absolute pregnancy-rate observation was 38% in the astaxanthin arm versus 11% in placebo. Mechanistically, astaxanthin is the most potent membrane-resident antioxidant tested in cell systems — it sits across the lipid bilayer with hydroxyl groups in the aqueous interface and a long polyene chain through the hydrocarbon core, quenching both lipid-phase and aqueous-phase reactive species. The 12mg/day dose on this site sits between the Comhaire trial dose (16mg) and the lower antioxidant-effect doses in non-fertility trials (4–8mg), and pairs well with CoQ10 (both are fat-soluble and absorb best with the same fat-containing meal).

PQQ — mitochondrial biogenesis

Where CoQ10 and astaxanthin protect existing mitochondria, PQQ activates the PGC-1α pathway that builds new ones. Chowanadisai 2010 (Journal of Biological Chemistry) demonstrated PQQ-induced mitochondrial biogenesis in mouse hepatocytes through CREB and PGC-1α phosphorylation. Harris 2013 (Journal of Nutritional Biochemistry) reported that 20mg/day PQQ in healthy adult humans reduced inflammatory markers (CRP, IL-6) and shifted urinary metabolite signatures consistent with increased mitochondrial activity. Hwang 2018 reported improved mitochondrial bioenergetics and reduced fatigue in adults supplementing 20mg/day PQQ over 8 weeks. The 20mg/day dose used in this collection matches the doses where the human pharmacodynamic effects have been documented; doses above 30mg/day have not added measured benefit.

The fertility stack — full dose, evidence, and use

CoQ10 400mg | Maximum Strength

The single most-studied compound for oocyte and sperm quality. Pharmaceutical-grade fermentation-derived CoQ10 (ubiquinone) at 400mg per softgel — the maximum-strength single-softgel dose, scalable to 600mg/day with 1.5 softgels. Trans-isomer verified by HPLC, made in USA, third-party tested for identity, potency, heavy metals, and microbiology. Take with the largest fat-containing meal of the day for absorption (CoQ10 is fat-soluble; absorption is roughly 2–3× higher with food). Pretreatment window for fertility goals: minimum 60 days before retrieval or attempted conception, with 90 days preferred. View CoQ10 400mg →

N-Acetyl Cysteine 600mg | NAC Glutathione Precursor

Pharmaceutical-grade NAC at 600mg/capsule — the dose used in the Sekhar GlyNAC trials, the Ciftci 2009 sperm trial, and most published PCOS/ovulation studies (which dose 1.2g/day = two capsules). Sulfur-amino-acid cysteine donor for hepatic glutathione synthesis. No magnesium stearate, no titanium dioxide, no soy. Standard fertility dose: 600mg twice daily morning and evening (1.2g/day total), or 600mg once daily for general support. Take with food to reduce the rare GI sulfur burping. Note: NAC has a "Ristow window" interaction with high-intensity exercise — see the contraindications section. View NAC 600mg →

Reduced Glutathione 500mg | Maximum Strength

Pre-formed reduced GSH at the maximum widely-bioavailable oral dose, paired with NAC for the substrate-and-product approach to glutathione status. Targets the master cytosolic antioxidant directly rather than depending entirely on hepatic synthesis. Take in the afternoon, on an empty stomach, away from sulfur-rich meals (allium-family vegetables) for best absorption. Pair with vitamin C (oral or liposomal) — vitamin C recycles oxidized glutathione (GSSG) back to reduced GSH, extending half-life. View Glutathione 500mg →

Astaxanthin 12mg | Antioxidant + Skin Support

Natural astaxanthin extracted from Haematococcus pluvialis microalgae — the same source used in the Comhaire 2005 sperm-quality trial. 12mg per softgel, suspended in olive oil for fat-soluble absorption. The 12mg dose sits between the Comhaire trial dose (16mg) and the lower antioxidant-effect doses (4–8mg), and is the most-published dose in skin and eye-health trials. Pair with CoQ10 — both are fat-soluble, both absorb best with breakfast, and the membrane-resident astaxanthin protects the inner-mitochondrial-membrane CoQ10 pool from re-oxidation. View Astaxanthin 12mg →

PQQ 20mg | Mitochondrial Biogenesis Activator

BioPQQ, the only commercial PQQ form with an FDA GRAS notification (No. 522, 2014), at 20mg/capsule with a small BioPerine cofactor for absorption. The 20mg/day dose corresponds to the published human pharmacodynamic studies; doses above 30mg have not added benefit. Take in the morning — PQQ is mildly stimulating in some users and the biogenesis signal benefits from daytime alignment with circadian metabolic peaks. Long-term supplementation (8+ weeks) is required before mitochondrial-mass-related effects emerge. View PQQ 20mg →

Three protocol tiers — entry, pre-conception, IVF pretreatment

Tier 1 — Entry / general pre-conception planning (couples 30+, no diagnosed concerns)

Minimum-effective stack for couples not yet trying or in the first trying-to-conceive cycle. CoQ10 400mg with breakfast, NAC 600mg with breakfast. Both partners take both. Adds redox protection and one cysteine donor at the foundational level. Daily cost: under $1.50 combined per partner. Time horizon: take continuously through trying-to-conceive cycles; if conception occurs, the male partner can continue, female partner discusses with prenatal physician (most clinicians continue CoQ10 in early pregnancy at the same or reduced dose, but this is a clinical decision).

Tier 2 — Active pre-conception (couples 35+, second trying-to-conceive cycle, mild concerns)

Stack expanded to four-of-five. Both partners: CoQ10 400mg with breakfast; NAC 600mg morning + 600mg evening (1.2g/day total); Astaxanthin 12mg with breakfast (alongside CoQ10). Female partner adds: Reduced Glutathione 500mg in the afternoon, on an empty stomach. Male partner adds: Reduced Glutathione 500mg in the afternoon (sperm-membrane redox priority). Time horizon: minimum 60 days before targeted cycle, ideally 90.

Tier 3 — IVF pretreatment / poor-responder profile / documented sperm-quality concerns

Full five-product stack at trial-validated doses. Both partners: CoQ10 400mg × 1.5 = 600mg/day with breakfast (the Bentov 2014 / Xu 2018 dose; 1 softgel breakfast + ½ softgel lunch); NAC 600mg morning + 600mg evening (1.2g/day, the Salehpour 2017 dose); Reduced Glutathione 500mg afternoon; Astaxanthin 12mg with breakfast; PQQ 20mg with breakfast. Time horizon: full 90 days before retrieval. Coordinate with your reproductive endocrinologist before starting Tier 3 if you are on any reproductive-cycle medication (clomiphene, letrozole, gonadotropins, GnRH agonists/antagonists), if you have been instructed to avoid antioxidants in any phase of your protocol, or if you are using assisted reproduction techniques where antioxidant timing has been clinically specified.

The 60–90 day pretreatment window

This is the single most important practical detail of the fertility stack and the one most often missed. The published IVF-pretreatment trials — Bentov 2014, Xu 2018, Comhaire 2005, Safarinejad 2009 — used pretreatment durations of 8 weeks to 6 months, settling on the 60–90 day window as the dominant clinical pattern. Three biological reasons make this duration the floor:

Spermatogenesis takes 74 days. The full cycle from spermatogonial stem cell to mature sperm leaving the epididymis is approximately 64 days of seminiferous-tubule development plus 10–14 days of epididymal maturation. Sperm in today's ejaculate are the product of the redox environment that existed in the testis 60–80 days ago. Antioxidant supplementation that begins less than 60 days before a target cycle is supplementing a sperm population whose maturation phase already happened.

Final oocyte maturation also takes ~90 days. While the oocyte itself has been arrested for decades, the final 85–90 days of antral follicular development determine which follicle ovulates that cycle and the bioenergetic status of its oocyte. Mitochondrial biogenesis kinetics require weeks-to-months to reflect changes in PGC-1α signaling. The Bentov and Xu trial designs assumed this timeline.

Glutathione status normalization is multi-week. The Sekhar 2021 GlyNAC trial in healthy older adults showed red-cell glutathione concentrations normalized over 24 weeks of daily NAC + glycine supplementation, with mitochondrial-function and biological-age markers moving in parallel. The fertility-relevant GSH compartments (follicular fluid, sperm cytoplasm) follow similar kinetics. A 4-week pretreatment is mostly priming; 8–12 weeks is when the GSH:GSSG ratio meaningfully shifts.

Practical implication: start the fertility stack at the moment of decision, not at the start of a cycle. If you are scheduling IVF, plan stack initiation no later than 60 days (preferably 90) before retrieval. If you are trying to conceive, run the stack continuously from the decision-to-try date.

Stacking guide — pairing the fertility stack with other protocols

With Foundational Health

The fertility stack pairs cleanly with the Foundational Health daily seven. Vitamin D3 + K2 MK-7, magnesium glycinate, omega-3 EPA + DHA, multi-collagen, vitamin C, taurine, and creatine all have independent fertility evidence: vitamin D3 status correlates with IVF outcomes (Polyzos 2014), DHA is the primary peroxidation-vulnerable lipid in sperm and the major omega-3 in human follicular fluid (Hammiche 2011), and creatine has emerging data on sperm motility and embryo development. The fertility-specific five layer on top of Foundational Health rather than replacing it.

With Mitochondrial Renewal

The Mitochondrial Renewal collection (Urolithin A, ALA, Spermidine, CoQ10) overlaps with fertility on CoQ10 and shares the mitochondrial-quality theme. Adding Urolithin A 500mg is reasonable in Tier 3 IVF pretreatment for the mitophagy signal (Andreux 2019), particularly for poor responders where mitochondrial-quality control is the suspected bottleneck. Spermidine has strong autophagy mechanism evidence but limited fertility-specific human data; reasonable as a long-term ground-state addition rather than a cycle-specific intervention.

With NAD+ Family

NAD+ precursors — NMN, NAD+ family products — restore NAD+/NADH ratios that decline with age, which has been characterized in mouse oocytes (Bertoldo 2020 in Cell Reports showed NMN restored fertility in aged mice). Human IVF data on NAD+ precursors is still emerging — there are ongoing trials but no published large RCTs at this writing. NMN is reasonable in Tier 3 IVF pretreatment as an adjunct, but should not displace CoQ10/NAC/GSH which have stronger published human fertility evidence.

With Antioxidants and Cardiovascular Longevity

Several products in the broader Antioxidants and Cardiovascular Longevity collections have fertility-relevant data: alpha-lipoic acid (Genazzani 2018 in PCOS), L-carnitine (Lenzi 2003 in male infertility — not currently in this catalog), curcumin (oxidative-stress-reduction in sperm). The fertility-specific five are the highest-evidence first stop; the antioxidants collection broadens redox coverage when warranted.

With Beauty and Anti-Aging

The Beauty & Anti-Aging collection (collagen peptides, hyaluronic acid, biotin) is independent of fertility but harmless to stack. Astaxanthin appears in both collections and only needs to be taken once daily.

Week-by-week — what to expect

Weeks 1–2: Subtle energy and recovery effects — most users notice a small lift in afternoon energy and faster recovery from exertion within 7–10 days, driven by CoQ10's bioenergetic effect. NAC takes 1–3 weeks to register a noticeable change in any subjective marker; some users notice slightly faster recovery from respiratory illnesses or hangovers earlier (mucolytic + glutathione effects). Astaxanthin and PQQ have no acute subjective effect — they are months-out signals.

Weeks 3–4: Glutathione status starts shifting. NAC + GSH pair has had 3 weeks of substrate-and-product loading. Hepatic glutathione is normalized in most users by week 4 if it was below normal at baseline. Subjective markers: clearer skin in some users, less response to oxidative-stress proxies (alcohol, intense exercise next-day fatigue).

Weeks 5–8: The first sperm cohort that completed meiosis under improved redox conditions is approaching maturity. Sperm-quality parameters (motility, viability, DNA-fragmentation index) start improving in the 6–12 week window in published trials. Female-side: antral follicle development for the cycles 2 months out is now happening under improved redox conditions.

Weeks 9–12: Full sperm cohort turnover is complete by week 11. Both Bentov 2014 and Xu 2018 used 8-to-9-week pretreatment windows for IVF outcomes; Comhaire 2005 used 12 weeks for sperm. Most semen-analysis improvements visible by week 12 in subfertile-baseline samples. PQQ-driven mitochondrial-biogenesis effects are reaching their measurable peak.

Beyond 12 weeks: Continuous use carries continuous benefit. The stack is well-tolerated long-term — CoQ10, NAC, glutathione, astaxanthin, and PQQ all have multi-year safety data at the doses on this site. There is no strong rationale to cycle off these compounds in the pre-conception period.

Drug interactions and contraindications — read this

CoQ10 + warfarin. CoQ10 has structural similarity to vitamin K and at high doses (>200mg/day) has been reported to reduce warfarin's anticoagulant effect via mild antagonism. If you are on warfarin, do not start CoQ10 without your prescribing physician adjusting your INR-monitoring schedule. CoQ10 does not interact materially with direct oral anticoagulants (DOACs — apixaban, rivaroxaban, dabigatran).

NAC + the Ristow window. NAC and other broad-spectrum antioxidants taken within the 60-minute window before high-intensity exercise have been shown in several trials (Ristow 2009, Paulsen 2014) to blunt the exercise-induced adaptive signaling response. Practical solution: take NAC at least 2 hours away from your training window. This is not a reason to avoid NAC — it is a reason to time it.

NAC + nitroglycerin. NAC potentiates the vasodilatory effect of nitroglycerin and can cause symptomatic hypotension or severe headache. Do not combine NAC with nitrate medications without prescribing physician oversight.

Glutathione + selenium / sulfur-rich meals. Not a drug interaction, an absorption interaction. Take oral GSH on an empty stomach away from cruciferous and allium vegetables for best uptake.

Astaxanthin + anticoagulants. Theoretical mild antiplatelet effect at high doses; no documented bleeding events at 12mg/day in published trials. Notify any anticoagulant-prescribing physician about your astaxanthin use.

PQQ + caffeine. Some users report mild stimulation from PQQ. If sensitive to stimulants, separate PQQ from morning coffee or take it later in the morning.

Active fertility medications. If you are on clomiphene, letrozole, gonadotropin injections (Gonal-F, Menopur, Follistim), GnRH agonists or antagonists (Lupron, Cetrotide), progesterone support (Crinone, Endometrin), HCG triggers, or any other reproductive-cycle medication: do not start the fertility stack without your reproductive endocrinologist's clearance. Some clinicians prescribe specific antioxidant timing protocols that may conflict; some explicitly suspend antioxidants in particular protocol phases. The published antioxidant trials are pretreatment trials, not concurrent-with-active-treatment trials.

Pregnancy. All five compounds in this stack have either GRAS status or human-pregnancy-population safety data, but the standard clinical default is to consult your prenatal physician for guidance once pregnancy is confirmed. Most clinicians continue CoQ10 (with or without dose reduction) and discontinue or reduce the others; this is a clinical decision, not a self-managed one.

Who this collection is for — and who it isn't

Strong fit: couples in active pre-conception planning; women aged 35+ approaching IVF or IUI cycles who want a science-grounded antioxidant pretreatment; men with documented sperm-quality concerns (subfertile semen analysis, prior IVF with low fertilization or poor embryo grade); adults with PCOS, endometriosis, or other oxidative-stress-driven reproductive conditions where supplementation is appropriate as part of a clinician-supervised protocol; couples interested in slowing the oxidative trajectory of gonadal aging in their 30s as a long-term posture.

Less obvious but still a fit: men on testosterone-replacement therapy (oxidative stress in TRT-induced suppressed spermatogenesis is real); recovering athletes considering a family in the next 12 months (high training loads stress redox systems); individuals with previously elevated DNA fragmentation index on semen analysis; partners of women with recurrent pregnancy loss where male-factor and oxidative-stress workup has been part of the evaluation.

Where this collection is not the right answer: diagnosed structural infertility (blocked tubes, severe varicocele, azoospermia) — the cause is not redox; primary ovarian insufficiency or premature menopause — antioxidants will not restore depleted ovarian reserve; severe male-factor infertility requiring ICSI — pretreatment may help but the procedure is the answer; individuals seeking pregnancy this cycle without 60-day pretreatment runway — the timeline mismatches; anyone using this in place of medical evaluation. This collection is supplementation to support normal reproductive cellular health — it is not a fertility treatment, and it does not replace clinical care.

Quality standards built into every fertility SKU

Every product in this collection is third-party tested for identity, potency, heavy metals, and microbiology in independent ISO/IEC 17025-accredited laboratories before lot release. Per-batch Certificates of Analysis are available — see the Quality and Sourcing page for the request workflow. Manufacturing is in cGMP-compliant facilities (FDA 21 CFR Part 111) with named partner sourcing where applicable: BioPerine for the PQQ formulation, fermentation-derived CoQ10 with HPLC-verified trans-isomer content, Haematococcus pluvialis–sourced natural astaxanthin (not synthetic). No artificial colors, no titanium dioxide, no magnesium stearate beyond what the formulation requires for capsule flow, no proprietary blends — every dose on the label is a named compound at a named milligram quantity. Allergens, vegan/vegetarian status, and excipient lists are disclosed on each product's ingredient sourcing page entry.

Frequently asked — fertility-specific

Do I have to take all five? What if I can only afford two or three?

Two-product entry: CoQ10 + NAC. That's the highest-evidence-density pair for the dollar. Three-product step-up: add Astaxanthin (sperm-side priority) or Reduced Glutathione (egg-side and pair-with-NAC priority). The full five is the IVF-pretreatment / Tier 3 stack. There is no harm in starting with two and adding from there as cycle planning firms up.

I'm a single male with no immediate pregnancy plans — does this stack make sense for me?

The CoQ10 + NAC + Astaxanthin core is a perfectly reasonable foundational longevity stack independent of fertility. The fertility-specific framing is the use case where the trial evidence is densest, but every compound has independent cardiovascular, mitochondrial, and antioxidant data. Many users on this stack are not in pre-conception planning at all.

I'm doing IVF in 30 days. Is it too late to start?

Honest answer: 30 days is short of the 60-day floor in published trials. The CoQ10 effect on oocyte mitochondrial function does have some 4-week data; the sperm-side compounds will not reflect a full cohort turnover in 30 days. Start anyway — partial benefit is better than no benefit, and the same supplementation will continue to work for any subsequent cycle if this one does not result in pregnancy. But align expectations: you are getting a partial dose of the published effect, not the full one.

My RE told me to avoid antioxidants during stimulation. What do I do?

Listen to your RE. Some clinicians suspend antioxidants during the active follicular-stimulation phase based on theoretical concerns about ROS-dependent ovarian signaling; others do not. This is a clinically active question with reasonable physicians on both sides. The pretreatment phase (before stimulation begins) is the trial-validated window — that is where your RE is most likely to support supplementation. Time the stack to your RE's protocol.

Are these the products my fertility clinic recommends?

Many fertility clinics recommend CoQ10 specifically by name for pretreatment of women 35+, and NAC is widely recommended for PCOS-related anovulation. Specific brands vary by clinic — most clinics recommend "any pharmaceutical-grade CoQ10 at 400–600mg/day" rather than naming a brand. The products on this site are dosed at and tested to the standard clinics use as their default recommendation.

Can I take all five with my prenatal vitamin?

Yes. There is no overlap with prenatal vitamin doses — prenatal vitamins do not include CoQ10, NAC, Astaxanthin, GSH, or PQQ at meaningful doses. Once pregnancy is confirmed, transition the question to your prenatal physician for guidance on continuation.

What about CoQ10 ubiquinol vs ubiquinone?

Ubiquinol (the reduced form) is marketed as more bioavailable, but the trials underpinning the fertility evidence base — Bentov 2014, Xu 2018, Safarinejad 2009 — used ubiquinone. Plasma concentrations achieved by both forms at equivalent oral doses converge after 1–2 weeks of supplementation as the cell maintains its preferred reduced/oxidized ratio internally. Ubiquinone at 400–600mg/day is the trial-validated path. Ubiquinol at 200–300mg/day is a reasonable equivalent if cost and pill-count are constraints.

Is there a "fertility bundle" I can buy instead of five products separately?

Not at present — the doses required for IVF pretreatment (CoQ10 600mg/day, NAC 1.2g/day) make a single all-in-one capsule impractical. The five separate SKUs let you scale dose by tier without overpaying. The closest pre-built bundle is the Longevity Stack Bundle, which is a different use case (NAD+/sirtuin priority, not redox priority).

How much does the full stack cost per month?

Tier 1 entry (CoQ10 + NAC): roughly $30–35/month per partner. Tier 2 active pre-conception (CoQ10 + NAC × 2 + GSH + Astaxanthin): roughly $80–95/month per partner. Tier 3 IVF pretreatment (full five at trial-validated doses): roughly $130–155/month per partner. The 60–90 day pretreatment window is therefore $260–465 per partner for the full course at Tier 3.

Do you ship internationally?

Yes — see the shipping policy for current zones and rates. The catalog ships from US warehouses with ~10-day delivery to most international addresses.

Can I return them if my fertility specialist tells me to stop?

Yes. The guarantee page details the return window. Unopened bottles are returnable for full refund; opened bottles are refundable on a partial basis. The full policy is on the refund policy page.

Reading list — go deeper

  • Bentov 2010 — The contribution of mitochondrial function to reproductive aging. The foundational review establishing the mitochondrial-DNA-mutation framing for age-related fertility decline. Fertility and Sterility.
  • Bentov 2014 — RCT of CoQ10 600mg/day in women aged 38–46 undergoing IVF. The trial halted early after positive signal made continued placebo unethical. Fertility and Sterility.
  • Xu 2018 — RCT of CoQ10 600mg/day in 169 poor-responder women, 60-day pretreatment. Significant improvements in oocyte count, fertilization rate, and high-quality embryo rate. Reproductive Biology and Endocrinology.
  • Ben-Meir 2015 — Mechanism paper. Aged-mouse oocytes have reduced CoQ10 biosynthesis enzymes and lower mitochondrial CoQ10 content; supplementation restored fertility markers. Aging Cell.
  • Comhaire 2005 — Astaxanthin 16mg/day for 3 months in 30 men with oligoasthenoteratozoospermia. 38% pregnancy rate vs 11% placebo. Asian Journal of Andrology.
  • Safarinejad 2009 — CoQ10 300mg/day in 212 men with idiopathic OAT. Significant improvements in density, motility, morphology. Journal of Urology.
  • Ciftci 2009 — NAC 600mg/day for 3 months in 60 men with idiopathic infertility. Significant motility and viscosity improvements. Urology.
  • Salehpour 2017 — NAC 1.2g/day vs metformin in clomiphene-resistant PCOS. Comparable ovulation and pregnancy rates. Reproductive BioMedicine Online.
  • Sekhar 2021 — GlyNAC (glycine + NAC) in healthy older adults. Normalized red-cell glutathione and biological-age markers over 24 weeks. Clinical and Translational Medicine.
  • Smits 2019 / Showell 2020 — Cochrane reviews of antioxidants in male and female subfertility. Low-to-moderate quality evidence for improved clinical pregnancy and live-birth.
  • Chowanadisai 2010 — PQQ-induced mitochondrial biogenesis through CREB and PGC-1α. Mechanism paper. Journal of Biological Chemistry.
  • Harris 2013 — PQQ 20mg/day in healthy adult humans. Reduced inflammatory markers, urinary metabolite shifts consistent with increased mitochondrial activity. Journal of Nutritional Biochemistry.
  • Aitken 2014 — Review of oxidative stress and DNA damage in human spermatozoa. The primary mechanistic paper for the male-side antioxidant rationale. Antioxidants & Redox Signaling.
  • Paszkowski 1995 — Reduced glutathione concentrations in follicular fluid correlate with oocyte quality and fertilization rate. Human Reproduction.

Primary references — citations behind every dose claim on this page

  1. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reproductive Biology and Endocrinology. 2008;3:28.
  2. Aitken RJ. Reactive oxygen species as mediators of sperm capacitation and pathological damage. Antioxidants & Redox Signaling. 2014;21(4):504–522.
  3. Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019;1(6):595–603.
  4. Ben-Meir A, Burstein E, Borrego-Alvarez A, et al. Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging. Aging Cell. 2015;14(5):887–895.
  5. Bentov Y, Casper RF. The aging oocyte — can mitochondrial function be improved? Fertility and Sterility. 2013;99(1):18–22.
  6. Bentov Y, Hannam T, Jurisicova A, et al. Coenzyme Q10 supplementation and oocyte aneuploidy in women undergoing IVF-ICSI treatment. Clinical Medicine Insights: Reproductive Health. 2014;8:31–36.
  7. Bertoldo MJ, Listijono DR, Ho WJ, et al. NAD+ repletion rescues female fertility during reproductive aging. Cell Reports. 2020;30(6):1670–1681.
  8. Chowanadisai W, Bauerly KA, Tchaparian E, et al. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1α expression. Journal of Biological Chemistry. 2010;285(1):142–152.
  9. Ciftci H, Verit A, Savas M, et al. Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status. Urology. 2009;74(1):73–76.
  10. Comhaire FH, El Garem Y, Mahmoud A, et al. Combined conventional/antioxidant Astaxanthin treatment for male infertility: a double-blind, randomized trial. Asian Journal of Andrology. 2005;7(3):257–262.
  11. Devi N, Boya C, Chhabra M, et al. N-acetyl-cysteine as adjuvant therapy in female infertility: a systematic review and meta-analysis. Journal of Basic and Clinical Physiology and Pharmacology. 2018;29(6):573–582.
  12. Florou P, Anagnostis P, Theocharis P, et al. Does coenzyme Q10 supplementation improve fertility outcomes in women undergoing assisted reproductive technology procedures? A systematic review and meta-analysis of randomized-controlled trials. Journal of Assisted Reproduction and Genetics. 2020;37(10):2377–2387.
  13. Hammiche F, Vujkovic M, Wijburg W, et al. Increased preconception omega-3 polyunsaturated fatty acid intake improves embryo morphology. Fertility and Sterility. 2011;95(5):1820–1823.
  14. Harris CB, Chowanadisai W, Mishchuk DO, et al. Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects. Journal of Nutritional Biochemistry. 2013;24(12):2076–2084.
  15. Paszkowski T, Traub AI, Robinson SY, McMaster D. Selenium dependent glutathione peroxidase activity in human follicular fluid. Clinica Chimica Acta. 1995;236(2):173–180.
  16. Polyzos NP, Anckaert E, Guzman L, et al. Vitamin D deficiency and pregnancy rates in women undergoing single embryo, blastocyst stage, transfer (SET) for IVF/ICSI. Human Reproduction. 2014;29(9):2032–2040.
  17. Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. PNAS. 2009;106(21):8665–8670.
  18. Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. 2015;54(2):251–263.
  19. Safarinejad MR. Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology. 2009;182(1):237–248.
  20. Salehpour S, Tohidi M, Akhound MR, et al. N-Acetylcysteine, a novel remedy for poly-cystic ovarian syndrome. Reproductive BioMedicine Online. 2017;35(2):200–205.
  21. Sekhar RV. GlyNAC supplementation improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, aging hallmarks, metabolic defects, muscle strength, cognitive decline, and body composition in older humans. Clinical and Translational Medicine. 2021;11(7):e372.
  22. Showell MG, Brown J, Clarke J, Hart RJ. Antioxidants for female subfertility. Cochrane Database of Systematic Reviews. 2020;8:CD007807.
  23. Smits RM, Mackenzie-Proctor R, Yazdani A, et al. Antioxidants for male subfertility. Cochrane Database of Systematic Reviews. 2019;3:CD007411.
  24. Thakker D, Raval A, Patel I, Walia R. N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Obstetrics and Gynecology International. 2015;2015:817849.
  25. Xu Y, Nisenblat V, Lu C, et al. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. Reproductive Biology and Endocrinology. 2018;16(1):29.
  26. Yeh J, Bowman MJ, Browne RW, Chen N. Reproductive aging results in a reconfigured ovarian antioxidant defense profile in rats. Fertility and Sterility. 2005;84 Suppl 2:1109–1113.

The fertility stack is part of a larger longevity catalog. Where to go next depends on whether you want to deepen the redox layer, broaden into mitochondrial renewal, or build the foundational health stack underneath. Foundational Health · Antioxidants · Mitochondrial Renewal · NAD+ Family · Cardiovascular Longevity · Beauty & Anti-Aging · Most Popular

Reference pages for the science and operational details on this collection: Our Science · How It Works · Protocols · Quality and Sourcing · Ingredient Sourcing · Getting Started · Guarantee · FAQ · About True Health Protocol

Disclaimer. Statements on this page have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease, including infertility. The published trial evidence summarized on this page is presented as scientific context for the dosing and stacking choices in the product line; it is not a clinical recommendation for any individual. Consult a qualified reproductive endocrinologist or fertility physician before initiating supplementation, particularly during active treatment cycles, pregnancy, or any condition affecting reproduction. The Cochrane evidence on antioxidants in subfertility is encouraging but graded low-to-moderate quality.
Skip to results list
Availability
Price
to
The highest price is $34.99
Clear
5 items

Filter

Availability
Price
to
The highest price is $34.99